VCEL: Vericel Corp.
About
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
Current Value
$55.831 Year Return
Current Value
$55.831 Year Return
Key Details
Market Cap
$2.76B
P/E Ratio
893.28
1Y Stock Return
55.60%
1Y Revenue Growth
22.48%
Dividend Yield
0.00%
Price to Book
10.7
Strategies that include VCEL
Stock's related to VCEL
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MSA | 49.64% | $6.61B | +1.70% | 1.19% |
| NVEE | 48.05% | $1.45B | -9.73% | 0.00% |
| AZZ | 47.79% | $2.60B | +78.85% | 0.78% |
| FBK | 46.84% | $2.55B | +64.80% | 1.25% |
| ASO | 46.65% | $3.24B | -4.48% | 0.93% |
| SCL | 46.63% | $1.69B | -6.79% | 2.01% |
| ATRO | 46.20% | $575.48M | +5.29% | 0.00% |
| KN | 45.92% | $1.60B | +12.19% | 0.00% |
| AMPL | 45.23% | $1.34B | -0.66% | 0.00% |
| NTB | 45.09% | - | - | 4.69% |
| CTS | 44.96% | $1.58B | +33.53% | 0.30% |
| BLFS | 44.94% | $1.04B | +64.64% | 0.00% |
| MBWM | 44.79% | $783.85M | +39.14% | 2.90% |
| ADEA | 44.75% | $1.20B | +17.45% | 1.74% |
| AIN | 44.73% | $2.61B | -0.13% | 1.26% |
| BY | 44.64% | $1.36B | +51.33% | 1.18% |
| KFRC | 44.61% | $1.10B | -8.71% | 0.66% |
| MODG | 44.54% | $1.56B | -25.89% | 0.00% |
| BHLB | 44.53% | $1.29B | +44.14% | 2.40% |
| SXI | 44.43% | $2.46B | +49.61% | 0.60% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LQDA | 0.07% | $859.91M | +53.94% | 0.00% |
| LNG | -0.10% | $49.37B | +24.99% | 0.82% |
| CYD | -0.11% | $364.46M | -2.94% | 4.26% |
| CPB | 0.21% | $12.96B | +7.08% | 3.40% |
| BTCT | 0.23% | $42.61M | +353.33% | 0.00% |
| RLMD | 0.23% | $89.92M | +1.36% | 0.00% |
| FENG | 0.25% | $13.37M | +96.77% | 0.00% |
| RNR | -0.31% | $13.74B | +23.09% | 0.58% |
| LU | -0.45% | $2.01B | -33.75% | 0.00% |
| EDU | 0.46% | $9.06B | -22.20% | 0.00% |
| LX | -0.47% | $446.80M | +57.07% | 4.21% |
| CAH | 0.51% | $28.64B | +12.14% | 1.70% |
| TEN | 0.53% | $606.64M | +3.32% | 4.39% |
| ZTO | -0.66% | $12.58B | -4.71% | 4.73% |
| SOC | -0.68% | $1.93B | +74.70% | 0.00% |
| VERX | 0.68% | $7.99B | +89.70% | 0.00% |
| OCFT | 0.93% | $80.95M | -30.38% | 0.00% |
| HIHO | 1.12% | $8.63M | 0.00% | 6.12% |
| CHD | 1.17% | $27.18B | +19.50% | 1.03% |
| BPT | 1.17% | $24.61M | -66.18% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PRPO | -16.97% | $9.10M | -13.65% | 0.00% |
| CYCN | -13.50% | $4.77M | -16.19% | 0.00% |
| HUSA | -10.03% | $16.69M | -11.56% | 0.00% |
| PDD | -9.51% | $163.43B | +0.29% | 0.00% |
| COR | -9.19% | $47.48B | +21.20% | 0.86% |
| OXBR | -9.07% | $19.05M | +178.18% | 0.00% |
| TCTM | -7.85% | $8.10M | -42.99% | 0.00% |
| SRRK | -7.71% | $2.61B | +134.91% | 0.00% |
| PRPH | -7.47% | $18.14M | -82.61% | 0.00% |
| PULM | -7.28% | $19.83M | +202.98% | 0.00% |
| TPST | -7.21% | $37.75M | -77.59% | 0.00% |
| EDSA | -6.61% | $7.11M | -21.79% | 0.00% |
| STG | -6.53% | $35.67M | +7.92% | 0.00% |
| VSTA | -6.46% | $204.94M | -39.33% | 0.00% |
| OCX | -6.12% | $42.93M | -36.09% | 0.00% |
| MCK | -6.07% | $78.15B | +35.51% | 0.42% |
| CORZ | -6.06% | $4.60B | +3,201.26% | 0.00% |
| WHF | -6.05% | - | - | 14.53% |
| CME | -5.93% | $82.76B | +9.21% | 1.98% |
| GAN | -5.81% | $83.39M | +21.19% | 0.00% |
ETF's related to VCEL
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| IWO | 59.51% | $12.56B | 0.24% |
| PSC | 58.30% | $702.17M | 0.38% |
| GSSC | 58.12% | $529.86M | 0.2% |
| MDYG | 58.12% | $2.80B | 0.15% |
| VTWO | 58.05% | $12.38B | 0.1% |
| XHE | 58.04% | $213.41M | 0.35% |
| VBK | 58.02% | $19.31B | 0.07% |
| IWM | 57.92% | $75.73B | 0.19% |
| ISCG | 57.79% | $640.00M | 0.06% |
| IJT | 57.64% | $6.64B | 0.18% |
| SLYG | 57.22% | $3.69B | 0.15% |
| ESML | 57.19% | $1.90B | 0.17% |
| ARKG | 57.11% | $1.13B | 0.75% |
| SMLF | 57.08% | $1.44B | 0.15% |
| SPSM | 56.97% | $12.72B | 0.03% |
| XSMO | 56.93% | $1.25B | 0.39% |
| NUSC | 56.88% | $1.27B | 0.31% |
| IJR | 56.88% | $90.05B | 0.06% |
| VXF | 56.85% | $21.54B | 0.06% |
| VB | 56.84% | $63.63B | 0.05% |
News
Yahoo
The United States market has experienced a notable upswing, climbing 3.9% over the last week and 33% over the past year, with earnings forecasted to grow by 16% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions.
Yahoo
A Relative Strength Rating upgrade for Vericel shows improving technical performance. Will it continue?
Yahoo
Vericel ( NASDAQ:VCEL ) Third Quarter 2024 Results Key Financial Results Revenue: US$57.9m (up 27% from 3Q 2023). Net...
Yahoo
Vericel Corp (VCEL) reports a 27% revenue increase and strategic advancements, positioning for sustained growth despite rising expenses.
Yahoo
Vericel (VCEL) delivered earnings and revenue surprises of 60% and 4.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
SeekingAlpha
MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ETCompany ParticipantsEric Burns - Vice President of Finance &...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.